Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Live biopsy study aims to predict immunotherapy response in cancer patients

NCT ID NCT07327489

Knowledge-focused Sponsor: Elephas Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This study is collecting live tumor samples from 2,000 cancer patients undergoing standard biopsies. Researchers will analyze these samples to understand how tumors respond to immunotherapy drugs outside the body. The goal is to develop a method to predict which patients will respond to treatment, potentially saving time and reducing side effects from ineffective therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could lead to a test that helps doctors predict which patients will benefit from immunotherapy, avoiding ineffective treatments.
What could go wrong
This is an observational study, not a treatment trial. It is early-stage research, and the findings may not translate into a reliable clinical test for years, if at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Apr 2038

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18 years or older, who are able and willing to provide written informed consent, have a suspected or confirmed cancer diagnosis and will be undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Able and willing to provide informed consent for participation 2. Age ≥18 years at time of consent. 3. Have a suspected or confirmed cancer diagnosis that is to be evaluated by means of a biopsy. 4. Subjects who are newly diagnosed or have suspected cancer must be treatment-naïve at the time of biopsy. All other subjects should have the biopsy performed before starting their next line of treatment. Exclusion Criteria: 1. Have a known auto-immune disease or prior condition (prior organ transplant, chronic kidney or liver disease) that renders them ineligible for immunotherapy (IO) treatment. 2. Severely immunocompromised person(s). Examples include patients on immunosuppressants, HIV positive patients on antiretrovirals, post transplantation patients. 3. Pregnant person(s).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumors cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer colorectal cancer colorectal neoplasm endometrial cancer endometrium neoplasm head and neck cancer Head and Neck Neoplasms kidney cancer liver cancer Liver Neoplasms Lynch syndrome melanoma neoplasm non-small cell lung carcinoma skin cancer skin neoplasm triple-negative breast carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumors cancer Bladder cancer Cancer Colorectal cancer DMMR colorectal cancer Endometrial cancer Head and neck cancer Immunotherapy Kidney cancer Liver cancer Melanoma (skin cancer) Msi-H colorectal cancer NSCLC (non-small cell lung cancer) Skin cancer TNBC - triple-negative breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Baylor Scott and White Biorepository

    NOT_YET_RECRUITING

    Temple, Texas, 76508, United States

  • Frederick Health Hospital

    RECRUITING

    Frederick, Maryland, 21702, United States

  • JPS Health Network

    RECRUITING

    Forth Worth, Texas, 76104, United States

  • Mercy Hospital - FTS

    RECRUITING

    Fort Smith, Arkansas, 72903, United States

  • Mercy Hospital - OKC

    RECRUITING

    Oklahoma City, Oklahoma, 73120, United States

  • Mercy Hospital - SPG

    RECRUITING

    Springfield, Missouri, 65804, United States

  • Mercy Hospital - South

    RECRUITING

    St Louis, Missouri, 63128, United States

  • Mercy Hospital -STL

    RECRUITING

    St Louis, Missouri, 63141, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.